Vytorin's label gets makeover to include SHARP results Cardiovascular Business In the SHARP (Study of Heart And Renal Protection) trial, Vytorin 10/20 mg lowered LDL-cholesterol in patients with moderate to severe chronic kidney disease (CKD), and major vascular events were reduced in the treatment group compared to placebo.

...